Deborah Dunsire is breaking an old pattern: The definition of madness is doing the same thing over and over, expecting a different outcome

In her first three years at Lundbeck, one of Deborah Dunsire's missions has been to rethink the pipeline and the way in which clinical trials are carried out, attempting to avoid more big and costly failures in clinical development at the company.

Photo: Lars Krabbe/Foto: Lars Krabbe/Ritzau Scanpix

Few and far between have been product launches at Lundbeck the past few years, including the three years led by Deborah Dunsire, with the only new launch being that of Vyepti, which is – for Lundbeck – a relatively new area: migraine.

Lundbeck, under the leadership of Dunsire, has chosen this approach in particular because of the problems with the lack of launches. The company has suffered several failures with substances in late stages, of which idalopirdine and Lu AF35700 have been the most noteworthy. This is a statistic that Dunsire is set on changing.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs